Article Type
Article
Abstract
Chronic rhinosinusitis (CRS) is a common health problem that requires both medical and surgical management. Recurrence after endoscopic sinus surgery and poor response to medical therapies with frequent need to systemic steroids are not uncommon. Understanding the pathophysiology and the endotypes of CRS along with identification of type 2 inflammatory mediators has helped in development of new medications. Biologics are monoclonal antibodies that can target different inflammatory mediators involved in the disease process. In this review, we present the latest evidence of biologics used in the treatment of CRS with nasal polyps.
We also highlight recent changes in treatment pathways that include the Food and Drug Administration‑approved dupilumab in managing difficult‑to‑treat CRS with nasal polyps. This review also includes the main reported adverse effects, potential risks, and discusses areas of future research.
Keywords:
biologics, chronic rhinosinusitis, dupilumab, mepolizumab, omalizumab
Recommended Citation
Herzallah IR.
Review article: New biologics in management of chronic rhinosinusitis with nasal polyps: current evidence and future perspectives.
Pan Arab J. Rhinol.
2021;
11 : 2-8.
Available at:
https://pajr.researchcommons.org/journal/vol11/iss1/2
DOI: https://doi.org/10.4103/pajr.pajr_27_20
